ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
Latest news
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
Science & Medicine
Read more ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025
Science & Medicine
Read more ImCheck to Present Updated ICT01 Data with Unprecedented High Rates of Complete Remission in AML at the AACR Annual Meeting 2025
Science & Medicine
Read more STAY IN TOUCH WITH OUR LATEST NEWS
Subscribe to receive our press releases and related news